Orlitroy
Orlitroy Uses, Dosage, Side Effects, Food Interaction and all others data.
Orlitroy is a reversible inhibitor of gastrointestinal lipase. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipase. The inactivated enzymes are thus unavailable to hydrolyze dietary fat in the form of triglycerides into absorbable free fatty acids and monoglycerides. As undigested triglycerides are not absorbed, the resulting caloric deficit may have a positive effect on weight control.
Orlitroy helps with weight reduction and maintenance by inhibiting the absorption of dietary fats via the inhibition of lipase enzymes.
| Trade Name | Orlitroy |
| Availability | Rx and/or OTC |
| Generic | Orlistat |
| Orlistat Other Names | Orlipastat, Orlipastatum, Orlistat, Tetrahydrolipstatin |
| Related Drugs | phentermine, semaglutide, Wegovy, Saxenda, liraglutide, Alli |
| Type | Capsule |
| Formula | C29H53NO5 |
| Weight | Average: 495.7348 Monoisotopic: 495.392373811 |
| Protein binding | Orlistat is >99% bound to plasma proteins (mainly lipoproteins and albumin). |
| Groups | Approved, Investigational |
| Therapeutic Class | Appetite suppressant drugs/Anti-obesity drugs |
| Manufacturer | Troikaa Pharmaceuticals Ltd |
| Available Country | India |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Orlitroy is used for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. Orlitroy is also used for the reduction of the risk of weight regain after prior weight loss. Orlitroy 120 mg is used for obese patients with an initial body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 in the presence of other risk factors (eg, hypertension, diabetes, dyslipidemia) and Orlitroy 60 mg is used for overweight & obese patients with an initial body mass index (BMI) ≥25 kg/m2.
Orlitroy is also used to associated treatment for these conditions: Weight Gain, Weight Reduction
How Orlitroy works
Orlitroy is a potent and selective inhibitor of various lipase enzymes responsible for the metabolism of fat. It acts in the gastrointestinal (GI) tract via covalent binding to the serine residues located on the active site of both gastric and pancreatic lipase. When orlistat is taken with food containing fat, it partially inhibits the hydrolysis of triglycerides. This decreases absorption of monoaclglycerides and free fatty acids, contributing to weight maintenance and weight loss.
Dosage
Orlitroy dosage
The recommended dose of Orlitroy is one 60 mg or 120 mg capsule three times a day with each main meal containing fat (during or up to 1 hour after the meal). The patient should be on a nutritionally balanced, reduced-calorie diet that contains approximately 30% of calories from fat. The daily intake of fat, carbohydrate, and protein should be distributed over three main meals. If a meal is occasionally missed or contains no fat, the dose of Orlitroy can be omitted.
Because Orlitroy has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene, patients should be counseled to take a multivitamin containing fat-soluble vitamin to ensure adequate nutrition. The vitamin supplement should be taken at least 2 hours before or after the administration of Orlitroy, such as at bedtime.
Side Effects
Commonly-observed adverse events associated with the use of Orlitroy include oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation, fecal incontinence.
Toxicity
The oral LD50 of orlistat is >5000 mg/kg in rats. Single orlistat doses of 800 mg and multiple doses of up to 400 mg three times a day for 15 days have been administered to healthy weight and obese subjects without clinically significant adverse findings. In addition, doses of 240 mg three times a day have been given to obese patients for 6 months without a significant adverse effects. Post-marketing reports of overdoses cases indicate no adverse events or adverse events that are similar to those reported with the recommended dose. If a significant overdose with orlistat occurs, the patient should be observed for at least 24 hours. Based on the results of clinical studies, systemic effects caused by orlistat are likely to be rapidly reversible.
Precaution
Patients should be advised to adhere to dietary guidelines. gastrointestinal events may increase when orlistat is taken with a diet high in fat (>30% of calories from fat). The daily intake of fat should be distributed over three main meals. If a meal is missed, the dose of orlistat may be omitted.
Interaction
May reduce the absorption of iodine salts and/or levothyroxine, fat-soluble vit (A, D, E, K) and beta carotene. May decrease plasma levels of ciclosporin and amiodarone. May decrease the efficacy of antiepileptic drugs (e.g. valproate, lamotrigine), antiretrovirals, antidepressants, antipsychotics (including lithium). Additive effect on glycaemic control with antidiabetics. May cause hormonal contraceptive failure. May enhance the anticoagulant effect of warfarin.
Food Interaction
- Take with food. Take with meals or up to 1 hour after a meal. Doses may be skipped for missed meals or fat-free meals.
Orlitroy multivitamins interaction
[Minor] Orlitroy decreases the absorption of fat-soluble vitamins.
Studies have shown a 30% reduction in beta-carotene absorption and a 60% reduction in tocopherol acetate absorption when coadministered with orlistat.
Vitamin supplements should be taken at least two hours before or after orlistat administration.
Orlitroy Drug Interaction
Moderate: lamotrigine, levothyroxineMinor: cholecalciferolUnknown: amphetamine / dextroamphetamine, zolpidem, aspirin, lorazepam, celecoxib, duloxetine, omega-3 polyunsaturated fatty acids, fluticasone nasal, clonazepam, atorvastatin, pregabalin, acetaminophen, cyanocobalamin, ascorbic acid, alprazolam, sertraline, cetirizine
Orlitroy Disease Interaction
Major: malabsorptionModerate: diabetics, (fat soluble) vitamin deficiency, nephrolithiasis
Volume of Distribution
Volume of distribution cannot be obtained because the absorption of orlistat is minimal. Orlitroy is minimally distributed to erythrocytes and is primarily bound to proteins.
Elimination Route
The systemic absorption and exposure of orlistat is low, however, systemic absorption of the drug is not required for orlistat activity. After an oral dose with 360 mg of radiolabeled orlistat, plasma radioactivity achieved a peak at about 8 hours. Plasma concentrations of unchanged parent drug were close to the lower end of detection limits (15
Half Life
The half-life of orlistat of the small amount of absorbed orlistat ranges between 1-2 hours.
Elimination Route
After single oral dose of radiolabled orlistat in both normal weight and obese volunteers fecal excretion of the unabsorbed drug was found to be the major route of elimination with 11,20 Fecal elimination of orlistat is estimated between 95-97%. Complete excretion by both routes occurs within in 3 to 5 days.
Pregnancy & Breastfeeding use
Pregnancy Category X. Orlitroy is contraindicated during pregnancy, because weight loss offers no potential benefit to a pregnant woman and may result in fetal harm.
It is not known whether Orlitroy is present in human milk or not. Caution should be exercised when Orlitroy is administered to a nursing woman.
Contraindication
Orlitroy is contraindicated in Pregnancy, Patients with chronic malabsorption syndrome, Patients with cholestasis, Patients with known hypersensitivity to Orlitroy or to any component of this product.
Special Warning
Pediatric use: Safety and effectiveness in pediatric patients below the age of 12 have not been established.
Acute Overdose
Single doses of 800 mg and multiple doses of up to 400 mg three times a day for 15 days have been studied in normal weight and obese subjects without significant adverse findings. If a significant overdose of orlistat occur, it is recommended that the patient be observed for 24 hours. Based on human and animal studies, any systemic effects attributable to the lipase inhibiting properties of orlistat should be rapidly reversible
Storage Condition
Store below 25°C; excursions permitted to 15° to 30°C. Keep the medicine out of reach of children.
Innovators Monograph
You find simplified version here Orlitroy
Orlitroy contains Orlistat see full prescribing information from innovator Orlitroy Monograph, Orlitroy MSDS, Orlitroy FDA label
FAQ
What is Orlitroy used for?
Orlitroy is used with an individualized low-calorie, low-fat diet and exercise program to help people lose weight. Prescription Orlitroy is used in overweight people who may also have high blood pressure, diabetes, high cholesterol, or heart disease.
How safe is Orlitroy?
The Food and Drug Administration published a safety review of orlistat in 2010 because of rare reports of serious liver injury in people using it. The FDA found no evidence to confirm that Orlitroy was the cause of the reported liver injuries.
How does Orlitroy work?
Orlitroy works by blocking the receptors in the brain that dopamine acts on. This prevents the excessive activity of dopamine and helps to control psychotic illness.
What are the common side effects of Orlitroy?
Common side effects of Orlitroy are include:
- Abdominal or stomach pain or discomfort
- back pain
- difficulty with moving
- gas with leaky bowel movements
- inability to hold bowel movement
- increases in bowel movements
- loss of bowel control
- oily bowel movements
- oily spotting of underclothes
Is Orlitroy safe during pregnancy?
Orlitroy should not be used during pregnancy as it may harm your unborn baby. Weight loss offers no potential benefit to a pregnant woman and may result in fetal harm.
Is Orlitroy safe during breastfeeding?
It is unlikely that Orlitroy will be absorbed by the infant in amounts that would adversely affect the breastfed infant.
Can I drink alcohol with Orlitroy?
Orlitroy does not interact with alcohol, so it is safe to drink alcohol while taking Orlitroy.
Can I drive after taking Orlitroy ?
You may feel less alert, drowsy or sleepy and have blurred vision while taking this medicine. If this happens, do not drive or use any tools or machines.
When should be taken of Orlitroy?
You should take it with liquids during the meal or up to 1 hour after eating. If you occasionally miss a meal or eat a meal that contains no fat, you should skip the dose of Orlitroy.
Can I take Orlitroy on empty stomach?
Orlitroy only works when there are fats in what you eat, so if you miss a meal or if you eat a meal which is fat-free then do not take a dose of Orlitroy.
How long does Orlitroy take to work?
You can expect to see results in 1-3 months; aiming to lose 5% of your starting body weight in 3 months.
What is the half life of Orlitroy?
The half-life of the absorbed orlistat is in the range of 1 to 2 hours.
How long does Orlitroy take to work?
You should not take Orlitroy for more than six months over the counter.
What happen if I forget to take Orlitroy?
If you forget to take a dose at the right time, take it as soon as you remember, then go on as before. However, do not take a double dose to make up for a forgotten tablet.
What happen If I stop taking Orlitroy?
Keep taking Orlitroy until your doctor tells you to stop. Do not stop taking your medicine just because you feel better as your illness may get worse or come back. Unless your doctor tells you otherwise, Orlitroy should not be stopped suddenly as this may cause withdrawal effects such as muscle stiffness or unusual body movements.
Can I overdose on Orlitroy ?
Yes, you can overdose on Orlitroy. Although the symptoms of such an overdose are not known, they are probably the same as the side effects. This includes: nausea, vomiting, diarrhea, gas, abdominal distress, oily feces and incontinence of feces.
Does Orlitroy effect fertility?
In Orlitroy group, significant improvement was observed in lipid profile at the end of 3 months. Conception rates were 40% and 16.7% and 3.3% in Orlitroy, metformin group and control group respectively.
Can Orlitroy affects my heart ?
Treatment with Orlitroy in conjunction with diet promotes significantly greater weight loss and cardiovascular risk factor reduction than diet alone amongst obese patients at high risk of future coronary events.
Can Orlitroy affect my kidneys?
Orlitroy use has been limited by troublesome but benign gastrointestinal side effects, it has more recently been associated with acute kidney injury (AKI).
Can Orlitroy affects my liver?
The liver injury that occurs during Orlitroy therapy ranges in severity from minor serum aminotransferase elevations to acute symptomatic hepatitis to severe acute liver failure that can be fatal or require emergency liver transplantation. There is no known therapy for orlistat induced liver injury.
Is Orlitroy good for weight loss?
Orlitroy promotes weight loss by decreasing the amount of dietary fat absorbed in your intestines.
Is Orlitroy harmful?
More specifically, the use of Orlitroy has been associated with several mild-to-moderate gastrointestinal adverse effects, such as oily stools, diarrhoea, abdominal pain and faecal spotting.
Can Orlitroy affect periods?
Women may also notice irregularities in the menstrual cycle while taking Orlitroy. Side effects are most common in the first few weeks after beginning the drug.
Does Orlitroy cause depression?
Evidence suggested one in 10 people taking the Orlitroy, whose Orlitroy name is Acomplia, may develop mental side-effects including low mood and depression, anxiety, irritability, nervousness and sleep disorders.
Can Orlitroy cause weight gain?
Orlitroy can cause weight gain also with other side effects.
